<DOC>
	<DOCNO>NCT00979654</DOCNO>
	<brief_summary>The objective study assess safety tolerability sifalimumab adult participant active systemic lupus erythematosus ( SLE ) active dermatomyositis ( DM ) polymyositis ( PM ) participate follow clinical study : MI-CP151 , MI-CP152 , MI-CP179 .</brief_summary>
	<brief_title>A Study Evaluate Long-Term Safety MEDI-545 Adult Participants With Systemic Lupus Erythematosus Myositis</brief_title>
	<detailed_description>The primary objective study evaluate long-term safety tolerability multiple intravenous ( IV ) dose sifalimumab adult participant active SLE DM PM previously treat investigational product ( sifalimumab placebo ) one follow sifalimumab clinical study : MI-CP151 , MI-CP152 , MI-CP179 .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 18 year old time screen . Written inform consent locally require authorization [ example , Health Insurance Portability Accountability Act ( HIPAA ) United States America ( USA ) , European Union ( EU ) Data Privacy Directive EU ] obtain participant/legal representative prior performing protocolrelated procedure , include Screening evaluation . Female participant childbearing potential sexually active must use must use 2 effective method avoid pregnancy Screening , must agree continue use precaution 26 week final dose investigational product . Males , unless surgically sterile , must use 2 effective method birth control female partner must agree continue use contraceptive precaution Screening 26 week final dose investigational product . If female , unless cervix surgically remove , Pap smear evidence malignancy within 6 month baseline ( define Day 1 ) . Must qualify receive investigational product ( sifalimumab placebo ) complete treatment period plus followup ( Day 266 participant MICP151 MICP152 Day 168 participant MICP179 ) one follow sifalimumab clinical study : MICP151 , MICP152 , MI‑CP179 , ability complete study period final visit , willing forego form experimental drug treatment study . Discontinued investigational product ( sifalimumab ) safety reason previous sifalimumab clinical study . For participant systemic lupus erythematosus ( SLE ) : Active severe unstable neuropsychiatric SLE , opinion investigator , would make participant unsuitable study unable fully understand informed consent , Active severe unstable renal disease opinion investigator would make participant unsuitable study For participant dermatomyositis ( DM ) polymyositis ( PM ) : Inclusion body myositis , cancerassociated myositis , myositis associate another connective tissue disease , environmentallyassociated myositis , drugrelated myopathy , history family history noninflammatory myopathy , scapular winging , atrophy , hypertrophy calf muscle , Active Hepatitis A , confirm positive test hepatitis B surface antigen ( HbsAg ) hepatitis B core antibody ( HbcAb ) hepatitis C serology . Isolated HbcAb positivity explore additional reflex test determine eligibility . Evidence active tuberculosis ( TB ) , either treat untreated , latent TB without completion appropriate course treatment appropriate ongoing prophylactic treatment , history severe viral infection , disseminate herpes , herpes encephalitis , ophthalmic herpes . Any following medication within 6 month entry study : Leflunomide great ( &gt; ) 20 milligram/day , Cyclophosphamide ( alkylating agent ) . Any following medication within 28 day entry study : Prednisone equivalent &gt; 30 mg/day &gt; 0.5 mg/kg , whichever less amount , Cyclosporine dose , Thalidomide dose , Interferon alpha 2b , Hydroxychloroquine &gt; 600 mg/day , Mycophenolate mofetil &gt; 3 gram/day , Methotrexate &gt; 25 mg/week , Azathioprine &gt; 3 mg/kilogram ( kg ) /day , Combination leflunomide methotrexate Nonstable dos one follow medication within 28 day entry study : Hydroxychloroquine , Mycophenolate mofetil , Methotrexate , Azathioprine At Screening blood test ( within 28 day entry study ) , follow : Total bilirubin &gt; upper limit normal ( ULN ) , Neutrophil count &lt; 1,500/microliter ( mcl ) ( &lt; 1.5 × 109/L ) , Platelet count &lt; 60,000/microliter ( mcl ) ( &lt; 60 × 109/L ) , Hemoglobin ( Hgb ) &lt; 7 gram per decilitre ( g/dL ) ( &lt; 70 g/L ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sifalimumab</keyword>
	<keyword>MEDI-545</keyword>
</DOC>